Alnylam Pharmaceuticals Inc. logo

Alnylam Pharmaceuticals Inc.

ALNY · United States

alnylam.com

Financials as of FY2025

A biopharmaceutical company that carries gene-silencing drug candidates through regulatory approval, then earns mainly from direct sales of its approved therapies plus collaboration and royalty payments from partner companies.

What stands out
  • Returns appear driven by leverage
At a glance
  • Depends onUpstream position: supplies 6 industries, depends on 3
  • ScaleMarket cap is $30.45B, higher than 95% of all stocks globally
  • FinancialsAltman Z-Score 4.24: safe zone
  • Interpretations9 currently firing — 9